SRSurya A. Reis

Surya A. Reis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Surya A. Reis has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Stephen J. Haggarty

    Department of Neurology, Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA

    2 shared publications
  • Alexander A. Kang

    Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA

    1 shared publication
  • Alison M. Goate

    Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

    1 shared publication
  • Ana M. Cuervo

    Department of Developmental and Molecular Biology and Institute for Aging Studies, Albert Einstein College of Medicine, New York, NY 10461, USA

    1 shared publication
  • Antonio Diaz

    Department of Developmental and Molecular Biology and Institute for Aging Studies, Albert Einstein College of Medicine, New York, NY 10461, USA

    1 shared publication
  • Cassidy R. Hinman

    Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA

    1 shared publication

Latest Publications

  • Open Access

    Mapping Endogenous Psychedelic Chemistry: Indolethylamine N -Methyltransferase (INMT) Localizes Proximal to the Golgi Apparatus of Human Neurons

    by Karis Will, Sergio Lázaro Martínez, Surya A. Reis, Stephen J. Haggarty

    N,N -dimethyltryptamine (DMT) is a serotonergic psychedelic with a history of ethnobotanical use and emerging clinical efficacy for neuropsychiatric disorders. Following Julius Axelrod’s pioneering studies showing DMT production in human tissues, DMT has been proposed as an endogenous neuromodulator because it is a serotonin 2A receptor (5-HT 2A R) agonist. However, the DMT-producing enzyme, indolethylamine N -methyltransferase (INMT), has not been characterized at the protein level in the human central nervous system. Here, we validated an anti-INMT antibody and used immunocytochemistry to show that INMT localizes in close proximity to other DMT biosynthetic enzymes near the cytosolic face of the cis -Golgi network in human induced pluripotent stem cell-derived neurons, with immunoreactivity observed across multiple neuronal Golgi phenotypes. Notably, both DMT-like and 5-HT 2A R immunoreactivity also partially localized in close proximity to the Golgi apparatus. Our results establish the first protein-level characterization of INMT in human neurons and identify the cis -Golgi network as a candidate microdomain for psychedelic tryptamine biosynthesis. We propose that INMT catalytic activity at the cis -Golgi network creates an enriched region of membrane-permeable psychedelic tryptamines that can access an intracellular 5-HT 2A R pool. These findings provide new tools and insights that can inform efforts to understand the mechanism of action of psychedelics under clinical investigation and to target endogenous tryptamines therapeutically. GRAPHICAL

  • A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy

    by Israel Hernandez, Gabriel Luna, Jennifer N. Rauch, Surya A. Reis, Michel Giroux, Celeste M. Karch, Daniel Boctor, Youssef E. Sibih, Nadia J. Storm, Antonio Diaz, et al.

    Targeting farnesylation of Rhes induces lysosomal-mediated tau degradation and reduces tau pathology in mice with tauopathy.